ClinicalTrials.Veeva

Menu

MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery

I

Institut Curie

Status and phase

Completed
Phase 3

Conditions

Malignant Neoplasm of Breast

Treatments

Drug: Saline
Drug: Ropivacaine

Study type

Interventional

Funder types

Other

Identifiers

NCT02408393
IC 2014-07

Details and patient eligibility

About

Compare the effect of paravertebral block (PVB) with Ropivacaine or placebo on the incidence of chronic pain 3 months after breast cancer surgery.

Full description

Before anesthesia, the second or third intercostal space is located. After an aspiration, 0.35 mL/kg of solution (ropivacaine 7.5 mg/mL or saline, maximum 30 mL) are injected into the paravertebral space. After 30 minutes, spread of PVB is evaluated by cold test on skin. Then, general anesthesia is induced.

Evaluation of the frequency of chronic pain at 3, 6 and 12 months by the Brief Pain Inventory (BPI) questionnaire and Neuropathic Pain Diagnostic (DN4) and Anxiety and depression evaluation by the Hospital Anxiety and Depression questionnaire (HAD) will be done.

Enrollment

380 patients

Sex

Female

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ treated by:

    • either breast-conserving surgery with axillary lymph node dissection
    • either radical surgery with or without axillary lymph node dissection.
  2. 18 years ≤ Age ≥ 85 years.

  3. ASA class 1, 2 or 3.

  4. No analgesic treatment for 2 days (no pre-existing chronic pain)

  5. If a biological control has been requested recently or deemed necessary by the Investigator, then it should be satisfactory : Adequate hematologic and hemostasis: neutrophil count (ANC) > 1500/mm3, haemoglobin > 9 g/dl and platelets > 75 000/mm3, prothrombin time > 70%, activated partial thromboplastin time < 1.5 X Upper Limit of Normal (ULN)

  6. Life expectancy ≥ 2 years.

  7. Signed informed consent form.

  8. Patient able to meet the self-assessments questionnaires (sufficient understanding assessments, proficiency in French)

  9. Patient affiliated with a health insurance scheme (beneficiary or legal)

There is no prohibition for people to take part simultaneously in another search and there is no exclusion cause at the end of the research period.

Exclusion criteria

  1. Ongoing neoplasm or history of malignancy other than breast cancer with the exception of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has not relapsed during the 5 years preceding inclusion in the trial.
  2. Bilateral breast carcinoma at the inclusion
  3. Male subjects.
  4. Metastatic breast carcinoma at diagnosis (M1).
  5. Severe heart, liver and respiratory failure (ASA 4)
  6. Allergy to local anesthetics and morphine.
  7. Use of analgesics during the 48 hours preceding the surgical procedure.
  8. History of breast surgery with painful sequelae
  9. Major deformation of the spine
  10. Puncture site infection
  11. History of substance abuse.
  12. Pregnant or lactating women, or women of childbearing potential without effective contraception
  13. Subjects deprived of their liberty or under guardianship (including temporary guardianship).
  14. Subjects unable to comply with medical follow-up of the trial for geographical, social or psychological reasons.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

380 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Saline (30 mL maximum)
Treatment:
Drug: Saline
Ropivacaine
Experimental group
Description:
Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
Treatment:
Drug: Ropivacaine

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems